[4-Oxo-2-phenyl-8-(piperazine-1-carbonyloxy)chromen-7-yl] piperazine-1-carboxylate;dihydrochloride

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: [4-Oxo-2-phenyl-8-(piperazine-1-carbonyloxy)chromen-7-yl] piperazine-1-carboxylate;dihydrochloride
• 英文别名: [4-oxo-2-phenyl-8-(piperazine-1-carbonyloxy)chromen-7-yl] piperazine-1-carboxylate;dihydrochloride
• 化学式: C25H28Cl2N4O6
• 分子量: 551.4
• InChiKey: NXHQGRPUHOVLLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  109
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] Substituted Dihydroxyflavone Derivatives, Compositions, and Methods Related Thereto<br/>[FR] DÉRIVÉS DE DIHYDROXYFLAVONE SUBSTITUÉS, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2020033960A1

  公开（公告）日：2020-02-13

  In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.

  在某些实施例中，该公开涉及杂环黄酮衍生物，例如本文提供的公式所描述的那些，制药组合物，以及相关方法。在某些实施例中，该公开涉及治疗或预防与BDNF和TrkB活性相关的疾病或症状的方法，如抑郁症、中风、雷特综合征、帕金森病和阿尔茨海默病，通过向需要的受试者投与本文披露的化合物组成的制药组合物的有效量。
• [EN] 7,8-DIHYDOXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] 7,8-DIHYDROXYFLAVONE ET DÉRIVÉS DE FLAVONE 7,8-SUBSTITUÉE, COMPOSITIONS ET MÉTHODES ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2014071134A1

  公开（公告）日：2014-05-08

  In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.

  在某些实施例中，本公开涉及7,8-二羟基黄酮和7,8-取代黄酮衍生物，例如本文提供的公式所描述的那些，以及与之相关的药物组合物和方法。在某些实施例中，本公开涉及治疗或预防与BDNF和TrkB活性相关的疾病或症状的方法，例如精神疾病、抑郁症、创伤后应激障碍和自闭症谱系障碍、中风、莱特综合征、帕金森病和阿尔茨海默病，通过向需要的受试者施用包含本文披露的化合物的药物组合物的有效量。在某些实施例中，考虑到本文披露的7,8-取代黄酮衍生物是7,8-二羟基黄酮和类似物的前药。
• 7,8-DIHYDROXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO
  申请人：Emory University

  公开号：EP2914585B1

  公开（公告）日：2018-03-07
• 7,8-DIHYDOXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO
  申请人：Emory University

  公开号：EP2914585A1

  公开（公告）日：2015-09-09